文献速递瓣膜病与结构性心脏病

NOTION-2试验:低危三叶或二叶式主动脉瓣狭窄患者TAVI与外科手术比较

Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial.
PubMed 文献 · Eur Heart J · 2024-01-01

NOTION-2试验将370例≤75岁低危重度症状性主动脉瓣狭窄患者1:1随机分配至TAVI或外科手术,其中100例为二叶式主动脉瓣。

要点

  • ≤75岁低危重度AS患者1年死亡、卒中或再住院率TAVI与外科手术无显著差异。
  • TAVI组大出血和新发房颤风险更低,但非致残性卒中、永久起搏器植入和中等以上瓣周漏风险更高。
  • 二叶式AS亚组TAVI事件率数值上高于手术(14.3% vs 3.9%),需进一步研究。

核心结论

  • 在≤75岁低危重度症状性AS患者中,TAVI与外科手术1年死亡、卒中或再住院复合终点发生率相似。
  • 年轻二叶式AS患者TAVI结局需谨慎并应进一步研究。

研究设计与样本

  • NOTION-2为随机对照试验,纳入≤75岁低危重度症状性AS患者共370例,1:1随机分配至TAVI或外科手术。
  • 患者平均年龄71.1岁,STS风险评分中位数1.1%,其中二叶式AS 100例。

主要发现

  • 与手术相比,TAVI组大出血和新发房颤风险更低,非致残性卒中、永久起搏器植入和中等以上瓣周漏风险更高。

临床怎么用

  • 对≤75岁低危三叶式AS患者,TAVI可作为与外科手术相当的选项,需综合评估出血、起搏器及瓣周漏风险。
  • 对年轻二叶式AS患者选择TAVI应谨慎,优先考虑外科手术或纳入进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Transcatheter aortic valve implantation (TAVI) has become the first choice to treat older patients with severe symptomatic aortic stenosis (AS). This study aimed to compare TAVI with surgery in low-risk patients ≤75 years of age, including both tricuspid and bicuspid AS. METHODS: The Nordic Aortic Valve Intervention (NOTION)-2 trial enrolled and 1:1 randomized low-risk patients aged ≤75 years with severe symptomatic AS to TAVI or surgery. The primary endpoint was a composite of all-cause mortality, stroke, or rehospitalization (related to the procedure, valve, or heart failure) at 12 months. RESULTS: A total of 370 patients were enrolled with a mean age of 71.1 years and a median Society of Thoracic Surgeons risk score of 1.1%. A total of 100 patients had bicuspid AS. The 1-year incidence of the primary endpoint was 10.2% in the TAVI group and 7.1% in the surgery group [absolute risk difference 3.1%; 95% confidence interval (CI), -2.7% to 8.8%; hazard ratio (HR) 1.4; 95% CI, 0.7-2.9; P = .3]. Patients with TAVI, when compared to surgery, had lower risk of major bleeding and new-onset atrial fibrillation and higher risk of non-disabling stroke, permanent pacemaker implantation, and moderate or greater paravalvular regurgitation. The risk of the primary composite endpoint was 8.7% and 8.3% in patients with tricuspid AS (HR 1.0; 95% CI, 0.5-2.3) and 14.3% and 3.9% in patients with bicuspid AS (HR 3.8; 95% CI, 0.8-18.5) treated with TAVI or surgery, respectively (P for interaction = .1). CONCLUSIONS: Among low-risk patients aged ≤75 years with severe symptomatic AS, the rate of the composite of death, stroke, or rehospitalization at 1 year was similar between TAVI and surgery. Transcatheter aortic valve implantation outcomes in young bicuspid AS patients warrant caution and should be further investigated. (NOTION-2, ClinicalTrials.gov, NCT02825134). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT02825134.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jørgensen TH, Thyregod HGH, Savontaus M, et al. Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J. 2024. PMID: 38747246. doi:10.1093/eurheartj/ehae331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。